Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Operating Income (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Operating Income for 14 consecutive years, with $38000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Income fell 99.09% year-over-year to $38000.0, compared with a TTM value of -$2.5 million through Dec 2025, up 77.98%, and an annual FY2025 reading of -$2.5 million, up 77.98% over the prior year.
  • Operating Income was $38000.0 for Q4 2025 at Heron Therapeutics, up from -$4.1 million in the prior quarter.
  • Across five years, Operating Income topped out at $4.2 million in Q4 2024 and bottomed at -$62.9 million in Q1 2022.
  • Average Operating Income over 5 years is -$25.9 million, with a median of -$22.6 million recorded in 2022.
  • Peak annual rise in Operating Income hit 165.74% in 2025, while the deepest fall reached 99.09% in 2025.
  • Year by year, Operating Income stood at -$53.5 million in 2021, then soared by 61.98% to -$20.4 million in 2022, then skyrocketed by 49.79% to -$10.2 million in 2023, then surged by 140.83% to $4.2 million in 2024, then crashed by 99.09% to $38000.0 in 2025.
  • Business Quant data shows Operating Income for HRTX at $38000.0 in Q4 2025, -$4.1 million in Q3 2025, and -$1.6 million in Q2 2025.